Clinical Chemistry AACC Online Job Center
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 50: 1702-1703, 2004; 10.1373/clinchem.2004.036715
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (36)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hertig, A.
Right arrow Articles by Rondeau, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hertig, A.
Right arrow Articles by Rondeau, E.
Related Collections
Right arrow Molecular Diagnostics and Genetics
Right arrow Evidence Based Laboratory Medicine and Test Utilization
(Clinical Chemistry. 2004;50:1702-1703.)
© 2004 American Association for Clinical Chemistry, Inc.

Letters to the Editor

Maternal Serum sFlt1 Concentration Is an Early and Reliable Predictive Marker of Preeclampsia

Alexandre Hertig1,a, Nadia Berkane2, Guillaume Lefevre3, Karine Toumi3, Hans-Peter Marti1, Jacqueline Capeau3, Serge Uzan2 and Eric Rondeau1,4

1 Institut National de la Santé et de la Recherche Médicale (INSERM) U4892 Department of Gynecology and Obstetrics3 Department of Biochemistry and4 Department of Nephrology, Hôpital Tenon, Paris, France

aAddress correspondence to this author at: Hôpital Tenon, 4 rue de la Chine, NA 75020 Paris, France. Fax 33-1-43645448; e-mail alexandre.hertig@tnn.ap-hop-paris.fr.

The first 20% of the full text of this article appears below.


To the Editor:

Preeclampsia is a leading cause of maternal and fetal morbidity and mortality worldwide. It occurs in two phases: abnormal implantation of the placenta leads to impaired placental blood flow, which in turn induces the release of a critical placental substance into the maternal circulation (1). Clinical onset usually occurs in the third trimester of pregnancy, long after initiation of the underlying process.

Recently, Maynard et al. (2) compared the gene expression profile in placental tissue from women with and without preeclampsia and identified soluble Flt1 (sFlt1), a vascular endothelial growth factor receptor, as a molecule of particular pathophysiologic interest. It is now suspected that trophoblastic injury markedly enhances placental sFlt1 production, antagonizing the endothelial protective role of vascular endothelial growth factor and/or placental growth factor and eventually leading to clinical preeclampsia (2)(3). A recent study pointed out that, compared with women with a retrospective diagnosis of normal pregnancy (i.e., without hypertension), preeclamptic women had increased serum sFlt1 several weeks before . . . [Full Text of this Article]




The following articles in journals at HighWire Press have cited this article:


Home page
 J. Am. Soc. Nephrol.Home page
S. E. Maynard and R. Thadhani
Pregnancy and the Kidney
J. Am. Soc. Nephrol., January 1, 2009; 20(1): 14 - 22.
[Abstract] [Full Text] [PDF]

Home page
 HypertensionHome page
B. Huppertz
Placental Origins of Preeclampsia: Challenging the Current Hypothesis
Hypertension, April 1, 2008; 51(4): 970 - 975.
[Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
N. Berkane, G. Lefevre, and A. Hertig
Angiogenic factors in preeclampsia: so complex, so simple?
Nephrol. Dial. Transplant., October 1, 2007; 22(10): 2753 - 2756.
[Full Text] [PDF]

Home page
 HypertensionHome page
S. Rana, S. A. Karumanchi, R. J. Levine, S. Venkatesha, J. A. Rauh-Hain, H. Tamez, and R. Thadhani
Sequential Changes in Antiangiogenic Factors in Early Pregnancy and Risk of Developing Preeclampsia
Hypertension, July 1, 2007; 50(1): 137 - 142.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
M. Cudmore, S. Ahmad, B. Al-Ani, T. Fujisawa, H. Coxall, K. Chudasama, L. R. Devey, S. J. Wigmore, A. Abbas, P. W. Hewett, et al.
Negative Regulation of Soluble Flt-1 and Soluble Endoglin Release by Heme Oxygenase-1
Circulation, April 3, 2007; 115(13): 1789 - 1797.
[Abstract] [Full Text] [PDF]

Home page
 HypertensionHome page
H. Stepan, A. Unversucht, N. Wessel, and R. Faber
Predictive Value of Maternal Angiogenic Factors in Second Trimester Pregnancies With Abnormal Uterine Perfusion
Hypertension, April 1, 2007; 49(4): 818 - 824.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
R. J. Levine, C. Lam, C. Qian, K. F. Yu, S. E. Maynard, B. P. Sachs, B. M. Sibai, F. H. Epstein, R. Romero, R. Thadhani, et al.
Soluble endoglin and other circulating antiangiogenic factors in preeclampsia.
N. Engl. J. Med., September 7, 2006; 355(10): 992 - 1005.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
K.-A. Wathen, E. Tuutti, U.-H. Stenman, H. Alfthan, E. Halmesmaki, P. Finne, O. Ylikorkala, and P. Vuorela
Maternal Serum-Soluble Vascular Endothelial Growth Factor Receptor-1 in Early Pregnancy Ending in Preeclampsia or Intrauterine Growth Retardation
J. Clin. Endocrinol. Metab., January 1, 2006; 91(1): 180 - 184.
[Abstract] [Full Text] [PDF]

Home page
 HypertensionHome page
C. Lam, K.-H. Lim, and S. A. Karumanchi
Circulating Angiogenic Factors in the Pathogenesis and Prediction of Preeclampsia
Hypertension, November 1, 2005; 46(5): 1077 - 1085.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2004 by the American Association for Clinical Chemistry.